Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Respiratory Research
Published in: Respiratory Research 1/2020

Open Access 01-12-2020 | Cystic Fibrosis | Review

Cathepsin S: investigating an old player in lung disease pathogenesis, comorbidities, and potential therapeutics

Authors: Ryan Brown, Sridesh Nath, Alnardo Lora, Ghassan Samaha, Ziyad Elgamal, Ryan Kaiser, Clifford Taggart, Sinéad Weldon, Patrick Geraghty

Published in: Respiratory Research | Issue 1/2020

Login to get access

Abstract

Dysregulated expression and activity of cathepsin S (CTSS), a lysosomal protease and a member of the cysteine cathepsin protease family, is linked to the pathogenesis of multiple diseases, including a number of conditions affecting the lungs. Extracellular CTSS has potent elastase activity and by processing cytokines and host defense proteins, it also plays a role in the regulation of inflammation. CTSS has also been linked to G-coupled protein receptor activation and possesses an important intracellular role in major histocompatibility complex class II antigen presentation. Modulated CTSS activity is also associated with pulmonary disease comorbidities, such as cancer, cardiovascular disease, and diabetes. CTSS is expressed in a wide variety of immune cells and is biologically active at neutral pH. Herein, we review the significance of CTSS signaling in pulmonary diseases and associated comorbidities. We also discuss CTSS as a plausible therapeutic target and describe recent and current clinical trials examining CTSS inhibition as a means for treatment.
Literature
1.
Lomas DA. Does protease-Antiprotease imbalance explain chronic obstructive pulmonary disease? Ann Am Thorac Soc. 2016;13(Suppl 2):S130–7.PubMed
2.
Patel S, Homaei A, El-Seedi HR, Akhtar N. Cathepsins: proteases that are vital for survival but can also be fatal. Biomed Pharmacother. 2018;105:526–32.PubMedPubMedCentralCrossRef
3.
Garcia-Touchard A, Henry TD, Sangiorgi G, Spagnoli LG, Mauriello A, Conover C, Schwartz RS. Extracellular proteases in atherosclerosis and restenosis. Arterioscler Thromb Vasc Biol. 2005;25:1119–27.PubMedCrossRef
4.
Taggart C, Mall MA, Lalmanach G, Cataldo D, Ludwig A, Janciauskiene S, Heath N, Meiners S, Overall CM, Schultz C, et al. Protean proteases: at the cutting edge of lung diseases. Eur Respir J. 2017;49(2):1501200.
5.
Leiberman J. Letter: familial variation of leukocyte lysosomal protease and serum alpha 1-antitrypsin as determinants in chronic obstructive pulmonary diseases. Am Rev Respir Dis. 1973;108:1019–20.PubMed
6.
Vogelmeier C, Hubbard RC, Fells GA, Schnebli HP, Thompson RC, Fritz H, Crystal RG. Anti-neutrophil elastase defense of the normal human respiratory epithelial surface provided by the secretory leukoprotease inhibitor. J Clin Invest. 1991;87:482–8.PubMedPubMedCentralCrossRef
7.
Wiedow O, Schroder JM, Gregory H, Young JA, Christophers E. Elafin: an elastase-specific inhibitor of human skin. Purification, characterization, and complete amino acid sequence. J Biol Chem. 1990;265:14791–5.PubMed
8.
Twigg MS, Brockbank S, Lowry P, FitzGerald SP, Taggart C, Weldon S. The role of serine proteases and Antiproteases in the cystic fibrosis lung. Mediat Inflamm. 2015;2015:293053.CrossRef
9.
Abboud RT, Vimalanathan S. Pathogenesis of COPD. Part I. the role of protease-antiprotease imbalance in emphysema. Int J Tuberc Lung Dis. 2008;12:361–7.PubMed
10.
Crisford H, Sapey E, Stockley RA. Proteinase 3; a potential target in chronic obstructive pulmonary disease and other chronic inflammatory diseases. Respir Res. 2018;19:180.PubMedPubMedCentralCrossRef
11.
Kirschke H, Schmidt I, Wiederanders B. Cathepsin S. the cysteine proteinase from bovine lymphoid tissue is distinct from cathepsin L (EC 3.4.22.15). Biochem J. 1986;240:455–9.PubMedPubMedCentralCrossRef
12.
Villadangos JA, Riese RJ, Peters C, Chapman HA, Ploegh HL. Degradation of mouse invariant chain: roles of cathepsins S and D and the influence of major histocompatibility complex polymorphism. J Exp Med. 1997;186:549–60.PubMedPubMedCentralCrossRef
13.
Turk V, Stoka V, Vasiljeva O, Renko M, Sun T, Turk B, Turk D. Cysteine cathepsins: from structure, function and regulation to new frontiers. Biochim Biophys Acta. 1824;2012:68–88.
14.
Turk B, Turk D, Turk V. Lysosomal cysteine proteases: more than scavengers. Biochim Biophys Acta. 2000;1477:98–111.PubMedCrossRef
15.
Bromme D, Nallaseth FS, Turk B. Production and activation of recombinant papain-like cysteine proteases. Methods. 2004;32:199–206.PubMedCrossRef
16.
Rossi A, Deveraux Q, Turk B, Sali A. Comprehensive search for cysteine cathepsins in the human genome. Biol Chem. 2004;385:363–72.PubMedCrossRef
17.
Veilleux A, Black WC, Gauthier JY, Mellon C, Percival MD, Tawa P, Falgueyret JP. Probing cathepsin S activity in whole blood by the activity-based probe BIL-DMK: cellular distribution in human leukocyte populations and evidence of diurnal modulation. Anal Biochem. 2011;411:43–9.PubMedCrossRef
18.
Shi GP, Sukhova GK, Kuzuya M, Ye Q, Du J, Zhang Y, Pan JH, Lu ML, Cheng XW, Iguchi A, et al. Deficiency of the cysteine protease cathepsin S impairs microvessel growth. Circ Res. 2003;92:493–500.PubMedCrossRef
19.
Shi GP, Sukhova GK, Grubb A, Ducharme A, Rhode LH, Lee RT, Ridker PM, Libby P, Chapman HA. Cystatin C deficiency in human atherosclerosis and aortic aneurysms. J Clin Invest. 1999;104:1191–7.PubMedPubMedCentralCrossRef
20.
Gupta S, Singh RK, Dastidar S, Ray A. Cysteine cathepsin S as an immunomodulatory target: present and future trends. Expert Opin Ther Targets. 2008;12:291–9.PubMedCrossRef
21.
Oei E, Kalb T, Beuria P, Allez M, Nakazawa A, Azuma M, Timony M, Stuart Z, Chen H, Sperber K. Accessory cell function of airway epithelial cells. Am J Physiol Lung Cell Mol Physiol. 2004;287:L318–31.PubMedCrossRef
22.
Shi GP, Munger JS, Meara JP, Rich DH, Chapman HA. Molecular cloning and expression of human alveolar macrophage cathepsin S, an elastinolytic cysteine protease. J Biol Chem. 1992;267:7258–62.PubMed
23.
Kirschke H, Wiederanders B, Bromme D, Rinne A. Cathepsin S from bovine spleen. Purification, distribution, intracellular localization and action on proteins. Biochem J. 1989;264:467–73.PubMedPubMedCentralCrossRef
24.
Wiederanders B, Bromme D, Kirschke H, von Figura K, Schmidt B, Peters C. Phylogenetic conservation of cysteine proteinases. Cloning and expression of a cDNA coding for human cathepsin S. J Biol Chem. 1992;267:13708–13.PubMed
25.
Rodriguez A, Webster P, Ortego J, Andrews NW. Lysosomes behave as Ca2+−regulated exocytic vesicles in fibroblasts and epithelial cells. J Cell Biol. 1997;137:93–104.PubMedPubMedCentralCrossRef
26.
Wiederanders B, Kaulmann G, Schilling K. Functions of propeptide parts in cysteine proteases. Curr Protein Pept Sci. 2003;4:309–26.PubMedCrossRef
27.
Caglic D, Turk B, Repnik U, Kosec G, Vasiljeva O, Turk V, Jedeszko C, Sloane BF, Miniejew C, Kindermann M, et al. The proinflammatory cytokines interleukin-1 α and tumor necrosis factor α promote the expression and secretion of proteolytically active cathepsin S from human chondrocytes. Biol Chem. 2013;394:307–16.PubMedCrossRef
28.
Lackman RL, Jamieson AM, Griffith JM, Geuze H, Cresswell P. Innate immune recognition triggers secretion of lysosomal enzymes by macrophages. Traffic. 2007;8:1179–89.PubMedCrossRef
29.
Yan D, Wang HW, Bowman RL, Joyce JA. STAT3 and STAT6 signaling pathways synergize to promote Cathepsin secretion from macrophages via IRE1alpha activation. Cell Rep. 2016;16:2914–27.PubMedPubMedCentralCrossRef
30.
Zheng T, Zhu Z, Wang Z, Homer RJ, Ma B, Riese RJ Jr, Chapman HA Jr, Shapiro SD, Elias JA. Inducible targeting of IL-13 to the adult lung causes matrix metalloproteinase- and cathepsin-dependent emphysema. J Clin Invest. 2000;106:1081–93.PubMedPubMedCentralCrossRef
31.
Wartenberg M, Andrault PM, Saidi A, Bigot P, Nadal-Desbarats L, Lecaille F, Lalmanach G. Oxidation of cathepsin S by major chemicals of cigarette smoke. Free Radic Biol Med. 2020;150:53–65.PubMedCrossRef
32.
Maubach G, Schilling K, Rommerskirch W, Wenz I, Schultz JE, Weber E, Wiederanders B. The inhibition of cathepsin S by its propeptide--specificity and mechanism of action. Eur J Biochem. 1997;250:745–50.PubMedCrossRef
33.
Mach L, Mort JS, Glossl J. Maturation of human procathepsin B. proenzyme activation and proteolytic processing of the precursor to the mature proteinase, in vitro, are primarily unimolecular processes. J Biol Chem. 1994;269:13030–5.PubMed
34.
Vasiljeva O, Dolinar M, Pungerčar JR, Turk V, Turk B. Recombinant human procathepsin S is capable of autocatalytic processing at neutral pH in the presence of glycosaminoglycans. FEBS Lett. 2005;579:1285–90.PubMedCrossRef
35.
Kopitar G, Dolinar M, Strukelj B, Pungercar J, Turk V. Folding and activation of human Procathepsin S from inclusion bodies produced in Escherichia coli. Eur J Biochem. 1996;236:558–62.PubMedCrossRef
36.
Novinec M, Lenarčič B, Turk B. Cysteine cathepsin activity regulation by glycosaminoglycans. Biomed Res Int. 2014;2014:309718.
37.
Potolicchio I, Carven GJ, Xu X, Stipp C, Riese RJ, Stern LJ, Santambrogio L. Proteomic analysis of microglia-derived exosomes: metabolic role of the aminopeptidase CD13 in neuropeptide catabolism. J Immunol. 2005;175:2237–43.PubMedCrossRef
38.
Cheng XW, Kuzuya M, Nakamura K, Di Q, Liu Z, Sasaki T, Kanda S, Jin H, Shi GP, Murohara T, et al. Localization of cysteine protease, cathepsin S, to the surface of vascular smooth muscle cells by association with integrin alphanubeta3. Am J Pathol. 2006;168:685–94.PubMedPubMedCentralCrossRef
39.
Nissler K, Strubel W, Kreusch S, Rommerskirch W, Weber E, Wiederanders B. The half-life of human procathepsin S. Eur J Biochem. 1999;263:717–25.PubMedCrossRef
40.
Ruckrich T, Brandenburg J, Cansier A, Muller M, Stevanovic S, Schilling K, Wiederanders B, Beck A, Melms A, Reich M, et al. Specificity of human cathepsin S determined by processing of peptide substrates and MHC class II-associated invariant chain. Biol Chem. 2006;387:1503–11.PubMedCrossRef
41.
Wilkinson RD, Williams R, Scott CJ, Burden RE. Cathepsin S: therapeutic, diagnostic, and prognostic potential. Biol Chem. 2015;396:867–82.PubMedCrossRef
42.
Zhou Y, Chen H, Liu L, Yu X, Sukhova GK, Yang M, Zhang L, Kyttaris VC, Tsokos GC, Stillman IE, et al. CD74 deficiency mitigates systemic lupus erythematosus-like autoimmunity and pathological findings in mice. J Immunol. 2017;198:2568–77.PubMedCrossRef
43.
44.
Oleszycka E, Moran HBT, Tynan GA, Hearnden CH, Coutts G, Campbell M, Allan SM, Scott CJ, Lavelle EC. IL-1α and inflammasome-independent IL-1β promote neutrophil infiltration following alum vaccination. FEBS J. 2016;283:9–24.PubMedCrossRef
45.
Vidak E, Javorsek U, Vizovisek M, Turk B. Cysteine Cathepsins and their extracellular roles: shaping the microenvironment. Cells. 2019;8(3):264.
46.
Shi GP, Webb AC, Foster KE, Knoll JH, Lemere CA, Munger JS, Chapman HA. Human cathepsin S: chromosomal localization, gene structure, and tissue distribution. J Biol Chem. 1994;269:11530–6.PubMed
47.
Vizovisek M, Fonovic M, Turk B. Cysteine cathepsins in extracellular matrix remodeling: extracellular matrix degradation and beyond. Matrix Biol. 2019;75-76:141–59.PubMedCrossRef
48.
Baugh M, Black D, Westwood P, Kinghorn E, McGregor K, Bruin J, Hamilton W, Dempster M, Claxton C, Cai J, et al. Therapeutic dosing of an orally active, selective cathepsin S inhibitor suppresses disease in models of autoimmunity. J Autoimmun. 2011;36:201–9.PubMedCrossRef
49.
Ainscough JS, Macleod T, McGonagle D, Brakefield R, Baron JM, Alase A, Wittmann M, Stacey M. Cathepsin S is the major activator of the psoriasis-associated proinflammatory cytokine IL-36gamma. Proc Natl Acad Sci U S A. 2017;114:E2748–e2757.PubMedPubMedCentralCrossRef
50.
51.
Repnik U, Starr AE, Overall CM, Turk B. Cysteine Cathepsins activate ELR chemokines and inactivate non-ELR chemokines. J Biol Chem. 2015;290:13800–11.PubMedPubMedCentralCrossRef
52.
Lecaille F, Lalmanach G, Andrault PM. Antimicrobial proteins and peptides in human lung diseases: a friend and foe partnership with host proteases. Biochimie. 2016;122:151–68.PubMedCrossRef
53.
Sobotic B, Vizovisek M, Vidmar R, Van Damme P, Gocheva V, Joyce JA, Gevaert K, Turk V, Turk B, Fonovic M. Proteomic identification of cysteine Cathepsin substrates shed from the surface of Cancer cells. Mol Cell Proteomics. 2015;14:2213–28.PubMedPubMedCentralCrossRef
54.
55.
Hunt JF, Fang K, Malik R, Snyder A, Malhotra N, Platts-Mills TA, Gaston B. Endogenous airway acidification. Implications for asthma pathophysiology. Am J Respir Crit Care Med. 2000;161:694–9.PubMedCrossRef
56.
Chapman HA, Riese RJ, Shi GP. Emerging roles for cysteine proteases in human biology. Annu Rev Physiol. 1997;59:63–88.PubMedCrossRef
57.
Geraghty P, Greene CM, O'Mahony M, O'Neill SJ, Taggart CC, McElvaney NG. Secretory leucocyte protease inhibitor inhibits interferon-gamma-induced cathepsin S expression. J Biol Chem. 2007;282:33389–95.PubMedCrossRef
58.
Andrault PM, Schamberger AC, Chazeirat T, Sizaret D, Renault J, Staab-Weijnitz CA, Hennen E, Petit-Courty A, Wartenberg M, Saidi A, et al. Cigarette smoke induces overexpression of active human cathepsin S in lungs from current smokers with or without COPD. Am J Physiol Lung Cell Mol Physiol. 2019;317:L625–38.PubMedCrossRef
59.
Nakajima T, Nakamura H, Owen CA, Yoshida S, Tsuduki K, Chubachi S, Shirahata T, Mashimo S, Nakamura M, Takahashi S, et al. Plasma Cathepsin S and Cathepsin S/cystatin C ratios are potential biomarkers for COPD. Dis Markers. 2016;2016:4093870.PubMedPubMedCentralCrossRef
60.
61.
Cimerman N, Brguljan PM, Krasovec M, Suskovic S, Kos J. Circadian and concentration profile of cathepsin S in sera from healthy subjects and asthmatic patients. Pflugers Arch. 2001;442:R204–6.PubMedCrossRef
62.
Zhou PP, Zhang WY, Li ZF, Chen YR, Kang XC, Jiang YX. Association between SNPs in the promoter region in cathepsin S and risk of asthma in Chinese Han population. Eur Rev Med Pharmacol Sci. 2016;20:2070–6.PubMed
63.
Li C, Chen Q, Jiang Y, Liu Z. Single nucleotide polymorphisms of cathepsin S and the risks of asthma attack induced by acaroid mites. Int J Clin Exp Med. 2015;8:1178–87.PubMedPubMedCentral
64.
Deschamps K, Cromlish W, Weicker S, Lamontagne S, Huszar SL, Gauthier JY, Mudgett JS, Guimond A, Romand R, Frossard N, et al. Genetic and pharmacological evaluation of cathepsin s in a mouse model of asthma. Am J Respir Cell Mol Biol. 2011;45:81–7.PubMedCrossRef
65.
Kim N, Bae KB, Kim MO, Yu DH, Kim HJ, Yuh HS, Ji YR, Park SJ, Kim S, Son KH, et al. Overexpression of cathepsin S induces chronic atopic dermatitis in mice. J Invest Dermatol. 2012;132:1169–76.PubMedCrossRef
66.
Vaszar LT, Nishimura T, Storey JD, Zhao G, Qiu D, Faul JL, Pearl RG, Kao PN. Longitudinal transcriptional analysis of developing neointimal vascular occlusion and pulmonary hypertension in rats. Physiol Genomics. 2004;17:150–6.PubMedCrossRef
67.
Hsu HC, Li HH, Lai YJ. Lai the role of smooth muscle Cathepsins in pulmonary arterial hypertension associated with systemic lupus erythematosus. Am J Respir Crit Care Med. 2016;193:2016.CrossRef
68.
Weiss-Sadan T, Gotsman I, Blum G. Cysteine proteases in atherosclerosis. FEBS J. 2017;284:1455–72.PubMedCrossRef
69.
Taggart CC, Greene CM, Smith SG, Levine RL, McCray PB Jr, O'Neill S, McElvaney NG. Inactivation of human beta-defensins 2 and 3 by elastolytic cathepsins. J Immunol. 2003;171:931–7.PubMedCrossRef
70.
Weldon S, McNally P, McAuley DF, Oglesby IK, Wohlford-Lenane CL, Bartlett JA, Scott CJ, McElvaney NG, Greene CM, McCray PB Jr. Taggart CC: miR-31 dysregulation in cystic fibrosis airways contributes to increased pulmonary cathepsin S production. Am J Respir Crit Care Med. 2014;190:165–74.PubMedPubMedCentralCrossRef
71.
Haerteis S, Krappitz M, Bertog M, Krappitz A, Baraznenok V, Henderson I, Lindstrom E, Murphy JE, Bunnett NW, Korbmacher C. Proteolytic activation of the epithelial sodium channel (ENaC) by the cysteine protease cathepsin-S. Pflugers Arch. 2012;464:353–65.PubMedPubMedCentralCrossRef
72.
Lecaille F, Naudin C, Sage J, Joulin-Giet A, Courty A, Andrault PM, Veldhuizen RA, Possmayer F, Lalmanach G. Specific cleavage of the lung surfactant protein a by human cathepsin S may impair its antibacterial properties. Int J Biochem Cell Biol. 2013;45:1701–9.PubMedCrossRef
73.
Small DM, Brown RR, Doherty DF, Abladey A, Zhou-Suckow Z, Delaney RJ, Kerrigan L, Dougan CM, Borensztajn KS, Holsinger L, et al. Targeting of cathepsin S reduces cystic fibrosis-like lung disease. Eur Respir J. 2019;53(3):1801523.
74.
Kehlet SN, Bager CL, Willumsen N, Dasgupta B, Brodmerkel C, Curran M, Brix S, Leeming DJ, Karsdal MA. Cathepsin-S degraded decorin are elevated in fibrotic lung disorders - development and biological validation of a new serum biomarker. BMC Pulm Med. 2017;17:110.PubMedPubMedCentralCrossRef
75.
Sevenich L, Bowman RL, Mason SD, Quail DF, Rapaport F, Elie BT, Brogi E, Brastianos PK, Hahn WC, Holsinger LJ, et al. Analysis of tumour- and stroma-supplied proteolytic networks reveals a brain-metastasis-promoting role for cathepsin S. Nat Cell Biol. 2014;16:876–88.PubMedPubMedCentralCrossRef
76.
Burden RE, Gormley JA, Jaquin TJ, Small DM, Quinn DJ, Hegarty SM, Ward C, Walker B, Johnston JA, Olwill SA, Scott CJ. Antibody-mediated inhibition of cathepsin S blocks colorectal tumor invasion and angiogenesis. Clin Cancer Res. 2009;15:6042–51.PubMedCrossRef
77.
Wang B, Sun J, Kitamoto S, Yang M, Grubb A, Chapman HA, Kalluri R, Shi GP. Cathepsin S controls angiogenesis and tumor growth via matrix-derived angiogenic factors. J Biol Chem. 2006;281:6020–9.PubMedCrossRef
78.
Veillard F, Saidi A, Burden RE, Scott CJ, Gillet L, Lecaille F, Lalmanach G. Cysteine cathepsins S and L modulate anti-angiogenic activities of human endostatin. J Biol Chem. 2011;286:37158–67.PubMedPubMedCentralCrossRef
79.
Hiroyuki Tanaka EY, Asai N, Yokoi T, Nishimura M, Nakao H, Yoneda M, Ohtsuka Y, Konno S, Yamada N. Cathepsin S, a new serum biomarker of sarcoidosis discovered by transcriptome analysis of alveolar macrophages. Sarcoidosis Vasc Diffuse Lung Dis. 2019;36(2):141–7.
80.
Ashley SL, Xia M, Murray S, O'Dwyer DN, Grant E, White ES, Flaherty KR, Martinez FJ, Moore BB. Six-SOMAmer index relating to immune, protease and Angiogenic functions predicts progression in IPF. PLoS One. 2016;11:e0159878.PubMedPubMedCentralCrossRef
81.
Nikaido T, Tanino Y, Wang X, Sato Y, Togawa R, Kikuchi M, Misa K, Saito K, Fukuhara N, Kawamata T, et al. Serum decorin is a potential prognostic biomarker in patients with acute exacerbation of idiopathic pulmonary fibrosis. J Thorac Dis. 2018;10:5346–58.PubMedPubMedCentralCrossRef
82.
Tjondrokoesoemo A, Schips TG, Sargent MA, Vanhoutte D, Kanisicak O, Prasad V, Lin SC, Maillet M, Molkentin JD. Cathepsin S contributes to the pathogenesis of muscular dystrophy in mice. J Biol Chem. 2016;291:9920–8.PubMedPubMedCentralCrossRef
83.
Edman MC, Janga SR, Meng Z, Bechtold M, Chen AF, Kim C, Naman L, Sarma A, Teekappanavar N, Kim AY, et al. Increased Cathepsin S activity associated with decreased protease inhibitory capacity contributes to altered tear proteins in Sjogren's syndrome patients. Sci Rep. 2018;8:11044.PubMedPubMedCentralCrossRef
84.
Klinngam W, Janga SR, Lee C, Ju Y, Yarber F, Shah M, Guo H, Wang D, MacKay JA, Edman MC, Hamm-Alvarez SF. Inhibition of Cathepsin S reduces lacrimal gland inflammation and increases tear flow in a mouse model of Sjogren's syndrome. Sci Rep. 2019;9:9559.PubMedPubMedCentralCrossRef
85.
Rupanagudi KV, Kulkarni OP, Lichtnekert J, Darisipudi MN, Mulay SR, Schott B, Gruner S, Haap W, Hartmann G, Anders HJ. Cathepsin S inhibition suppresses systemic lupus erythematosus and lupus nephritis because cathepsin S is essential for MHC class II-mediated CD4 T cell and B cell priming. Ann Rheum Dis. 2015;74:452–63.PubMedCrossRef
86.
87.
Sukhova GK, Shi GP, Simon DI, Chapman HA, Libby P. Expression of the elastolytic cathepsins S and K in human atheroma and regulation of their production in smooth muscle cells. J Clin Invest. 1998;102:576–83.PubMedPubMedCentralCrossRef
88.
Qin Y, Cao X, Guo J, Zhang Y, Pan L, Zhang H, Li H, Tang C, Du J, Shi GP. Deficiency of cathepsin S attenuates angiotensin II-induced abdominal aortic aneurysm formation in apolipoprotein E-deficient mice. Cardiovasc Res. 2012;96:401–10.PubMedPubMedCentralCrossRef
89.
Figueiredo JL, Aikawa M, Zheng C, Aaron J, Lax L, Libby P, de Lima Filho JL, Gruener S, Fingerle J, Haap W, et al. Selective cathepsin S inhibition attenuates atherosclerosis in apolipoprotein E-deficient mice with chronic renal disease. Am J Pathol. 2015;185:1156–66.PubMedPubMedCentralCrossRef
90.
Lafarge JC, Pini M, Pelloux V, Orasanu G, Hartmann G, Venteclef N, Sulpice T, Shi GP, Clement K, Guerre-Millo M. Cathepsin S inhibition lowers blood glucose levels in mice. Diabetologia. 2014;57:1674–83.PubMedCrossRef
91.
Naour N, Rouault C, Fellahi S, Lavoie ME, Poitou C, Keophiphath M, Eberle D, Shoelson S, Rizkalla S, Bastard JP, et al. Cathepsins in human obesity: changes in energy balance predominantly affect cathepsin s in adipose tissue and in circulation. J Clin Endocrinol Metab. 2010;95:1861–8.PubMedCrossRef
92.
Reddy VB, Shimada SG, Sikand P, Lamotte RH, Lerner EA. Cathepsin S elicits itch and signals via protease-activated receptors. J Invest Dermatol. 2010;130:1468–70.PubMedPubMedCentralCrossRef
93.
Jimenez-Vargas NN, Pattison LA, Zhao P, Lieu T, Latorre R, Jensen DD, Castro J, Aurelio L, Le GT, Flynn B, et al. Protease-activated receptor-2 in endosomes signals persistent pain of irritable bowel syndrome. Proc Natl Acad Sci U S A. 2018;115:E7438–47.PubMedPubMedCentralCrossRef
94.
95.
96.
Bosse Y. Genetics of chronic obstructive pulmonary disease: a succinct review, future avenues and prospective clinical applications. Pharmacogenomics. 2009;10:655–67.PubMedCrossRef
97.
Gao SL, Wang YH, Li CY, Yang LW, Zou BA, Chen ZG, Yao WM, Song ZQ, Cheng JF, Lin ZY, Liu G. A highly significant association between Cathepsin S gene polymorphisms rs12068264 and chronic obstructive pulmonary disease susceptibility in Han Chinese population. Biosci Rep. 2018;38(4):BSR20180410.
98.
Zheng T, Kang MJ, Crothers K, Zhu Z, Liu W, Lee CG, Rabach LA, Chapman HA, Homer RJ, Aldous D, et al. Role of cathepsin S-dependent epithelial cell apoptosis in IFN-gamma-induced alveolar remodeling and pulmonary emphysema. J Immunol. 2005;174:8106–15.PubMedCrossRef
99.
Doherty DF, Nath S, Poon J, Foronjy RF, Ohlmeyer M, Dabo AJ, Salathe M, Birrell M, Belvisi M, Baumlin N, et al. Protein phosphatase 2A reduces cigarette smoke-induced Cathepsin S and loss of lung function. Am J Respir Crit Care Med. 2019;200:51–62.PubMedPubMedCentralCrossRef
100.
Geraghty P, Eden E, Pillai M, Campos M, McElvaney NG. Foronjy RF: alpha1-antitrypsin activates protein phosphatase 2A to counter lung inflammatory responses. Am J Respir Crit Care Med. 2014;190:1229–42.PubMedPubMedCentralCrossRef
101.
Wu KY, Zhu Z, Wang Y, Yin SJ, Li GY, Kong ZB, Liu Y, Li H, Song S. Liu H: [the association between Cathepsin S and pulmonary function and CT phenotypes in patients with chronic obstructive pulmonary disease]. Zhonghua Jie He He Hu Xi Za Zhi. 2019;42:372–7.PubMed
102.
Scott A, Lugg ST, Aldridge K, Lewis KE, Bowden A, Mahida RY, Grudzinska FS, Dosanjh D, Parekh D, Foronjy R, et al. Pro-inflammatory effects of e-cigarette vapour condensate on human alveolar macrophages. Thorax. 2018;73:1161–9.PubMedCrossRef
103.
Glynos C, Bibli SI, Katsaounou P, Pavlidou A, Magkou C, Karavana V, Topouzis S, Kalomenidis I, Zakynthinos S, Papapetropoulos A. Comparison of the effects of e-cigarette vapor with cigarette smoke on lung function and inflammation in mice. Am J Physiol Lung Cell Mol Physiol. 2018;315:L662–l672.PubMedCrossRef
104.
Garcia-Arcos I, Geraghty P, Baumlin N, Campos M, Dabo AJ, Jundi B, Cummins N, Eden E, Grosche A, Salathe M, Foronjy R. Chronic electronic cigarette exposure in mice induces features of COPD in a nicotine-dependent manner. Thorax. 2016;71:1119–29.PubMedCrossRef
105.
Kostikas K, Papatheodorou G, Ganas K, Psathakis K, Panagou P, Loukides S. pH in expired breath condensate of patients with inflammatory airway diseases. Am J Respir Crit Care Med. 2002;165:1364–70.PubMedCrossRef
106.
107.
108.
Fajardo I, Svensson L, Bucht A, Pejler G. Increased levels of hypoxia-sensitive proteins in allergic airway inflammation. Am J Respir Crit Care Med. 2004;170:477–84.PubMedCrossRef
109.
Lewis CC, Yang JY, Huang X, Banerjee SK, Blackburn MR, Baluk P, McDonald DM, Blackwell TS, Nagabhushanam V, Peters W, et al. Disease-specific gene expression profiling in multiple models of lung disease. Am J Respir Crit Care Med. 2008;177:376–87.PubMedCrossRef
110.
Riese RJ, Mitchell RN, Villadangos JA, Shi GP, Palmer JT, Karp ER, De Sanctis GT, Ploegh HL, Chapman HA. Cathepsin S activity regulates antigen presentation and immunity. J Clin Invest. 1998;101:2351–63.PubMedPubMedCentralCrossRef
111.
112.
Cavailles A, Brinchault-Rabin G, Dixmier A, Goupil F, Gut-Gobert C, Marchand-Adam S, Meurice JC, Morel H, Person-Tacnet C, Leroyer C, Diot P. Comorbidities of COPD. Eur Respir Rev. 2013;22:454–75.PubMedCrossRef
113.
Ronan NJ, Elborn JS, Plant BJ. Current and emerging comorbidities in cystic fibrosis. Presse Med. 2017;46:e125–38.PubMedCrossRef
114.
115.
Chang CJ, Hsu HC, Ho WJ, Chang GJ, Pang JS, Chen WJ, Huang CC, Lai YJ. Cathepsin S promotes the development of pulmonary arterial hypertension. Am J Physiol Lung Cell Mol Physiol. 2019;317:L1–L13.PubMedCrossRef
116.
Hamblin M, Chang L, Zhang H, Yang K, Zhang J, Chen YE. Vascular smooth muscle cell peroxisome proliferator-activated receptor-gamma deletion promotes abdominal aortic aneurysms. J Vasc Surg. 2010;52:984–93.PubMedPubMedCentralCrossRef
117.
Yao L, Yang Y, He G, Ou C, Wang L, Liu K. Global proteomics deciphered novel-function of Osthole against pulmonary arterial hypertension. Sci Rep. 2018;8:5556.PubMedPubMedCentralCrossRef
118.
Evans TI, Joo NS, Keiser NW, Yan Z, Tyler SR, Xie W, Zhang Y, Hsiao JJ, Cho HJ, Wright ME, et al. Glandular proteome identifies Antiprotease cystatin C as a critical modulator of airway hydration and clearance. Am J Respir Cell Mol Biol. 2016;54:469–81.PubMedPubMedCentralCrossRef
119.
Engelhardt JF, Yankaskas JR, Ernst SA, Yang Y, Marino CR, Boucher RC, Cohn JA, Wilson JM. Submucosal glands are the predominant site of CFTR expression in the human bronchus. Nat Genet. 1992;2:240–8.PubMedCrossRef
120.
Sagel SD, Sontag MK, Wagener JS, Kapsner RK, Osberg I, Accurso FJ. Induced sputum inflammatory measures correlate with lung function in children with cystic fibrosis. J Pediatr. 2002;141:811–7.PubMedCrossRef
121.
Rogan MP, Taggart CC, Greene CM, Murphy PG, O'Neill SJ, McElvaney NG. Loss of microbicidal activity and increased formation of biofilm due to decreased lactoferrin activity in patients with cystic fibrosis. J Infect Dis. 2004;190:1245–53.PubMedCrossRef
122.
Martin SL, Moffitt KL, McDowell A, Greenan C, Bright-Thomas RJ, Jones AM, Webb AK, Elborn JS. Association of airway cathepsin B and S with inflammation in cystic fibrosis. Pediatr Pulmonol. 2010;45:860–8.PubMedCrossRef
123.
Hentschel J, Fischer N, Janhsen WK, Markert UR, Lehmann T, Sonnemann J, Boer K, Pfister W, Hipler UC, Mainz JG. Protease-antiprotease imbalances differ between cystic fibrosis patients' upper and lower airway secretions. J Cyst Fibros. 2015;14:324–33.PubMedCrossRef
124.
Andrault PM, Samsonov SA, Weber G, Coquet L, Nazmi K, Bolscher JG, Lalmanach AC, Jouenne T, Bromme D, Pisabarro MT, et al. Antimicrobial peptide LL-37 is both a substrate of Cathepsins S and K and a selective inhibitor of Cathepsin L. Biochemistry. 2015;54:2785–98.PubMedCrossRef
125.
Coakley RD, Grubb BR, Paradiso AM, Gatzy JT, Johnson LG, Kreda SM, O'Neal WK, Boucher RC. Abnormal surface liquid pH regulation by cultured cystic fibrosis bronchial epithelium. Proc Natl Acad Sci U S A. 2003;100:16083–8.PubMedPubMedCentralCrossRef
126.
127.
Sutoo S, Maeda T, Suzuki A, Kato Y. Adaptation to chronic acidic extracellular pH elicits a sustained increase in lung cancer cell invasion and metastasis. Clin Exp Metastasis. 2020;37:133–44.PubMedCrossRef
128.
Jobs E, Ingelsson E, Riserus U, Nerpin E, Jobs M, Sundstrom J, Basu S, Larsson A, Lind L, Arnlov J. Association between serum cathepsin S and mortality in older adults. JAMA. 2011;306:1113–21.PubMedCrossRef
129.
130.
Beroukhim R, Mermel CH, Porter D, Wei G, Raychaudhuri S, Donovan J, Barretina J, Boehm JS, Dobson J, Urashima M, et al. The landscape of somatic copy-number alteration across human cancers. Nature. 2010;463:899–905.PubMedPubMedCentralCrossRef
131.
Willumsen N, Bager CL, Leeming DJ, Bay-Jensen AC, Karsdal MA. Nidogen-1 degraded by Cathepsin S can be quantified in serum and is associated with non-Small cell lung Cancer. Neoplasia. 2017;19:271–8.PubMedPubMedCentralCrossRef
132.
Rath B, Klameth L, Plangger A, Hochmair M, Ulsperger E, Huk I, Zeillinger R, Hamilton G. Expression of proteolytic enzymes by Small cell lung Cancer circulating tumor cell lines. Cancers (Basel). 2019;11(1):114.
133.
Lin HH, Chen SJ, Shen MR, Huang YT, Hsieh HP, Lin SY, Lin CC, Chang WW, Chang JY. Lysosomal cysteine protease cathepsin S is involved in cancer cell motility by regulating store-operated ca(2+) entry. Biochim Biophys Acta Mol Cell Res. 2019;1866:118517.PubMedCrossRef
134.
135.
Nader CP, Cidem A, Verrills NM, Ammit AJ. Protein phosphatase 2A (PP2A): a key phosphatase in the progression of chronic obstructive pulmonary disease (COPD) to lung cancer. Respir Res. 2019;20:222.PubMedPubMedCentralCrossRef
136.
Nath S, Ohlmeyer M, Salathe MA, Poon J, Baumlin N, Foronjy RF, Geraghty P. Chronic cigarette smoke exposure subdues PP2A activity by enhancing expression of the oncogene CIP2A. Am J Respir Cell Mol Biol. 2018;59:695–705.PubMedCrossRef
137.
Raghu G, Freudenberger TD, Yang S, Curtis JR, Spada C, Hayes J, Sillery JK, Pope CE 2nd, Pellegrini CA. High prevalence of abnormal acid gastro-oesophageal reflux in idiopathic pulmonary fibrosis. Eur Respir J. 2006;27:136–42.PubMedCrossRef
138.
Kasabova M, Joulin-Giet A, Lecaille F, Saidi A, Marchand-Adam S, Lalmanach G. Human cystatin C: a new biomarker of idiopathic pulmonary fibrosis? Proteomics Clin Appl. 2014;8:447–53.PubMedCrossRef
139.
Hirakawa H, Pierce RA, Bingol-Karakoc G, Karaaslan C, Weng M, Shi GP, Saad A, Weber E, Mariani TJ, Starcher B, et al. Cathepsin S deficiency confers protection from neonatal hyperoxia-induced lung injury. Am J Respir Crit Care Med. 2007;176:778–85.PubMedPubMedCentralCrossRef
140.
Schwarzkopf L, Witt S, Waelscher J, Polke M, Kreuter M. Associations between comorbidities, their treatment and survival in patients with interstitial lung diseases - a claims data analysis. Respir Res. 2018;19:73.PubMedPubMedCentralCrossRef
141.
Chetty U, McLean G, Morrison D, Agur K, Guthrie B, Mercer SW. Chronic obstructive pulmonary disease and comorbidities: a large cross-sectional study in primary care. Br J Gen Pract. 2017;67:e321–8.PubMedCrossRef
142.
Thanei S, Theron M, Silva AP, Reis B, Branco L, Schirmbeck L, Kolb FA, Haap W, Schindler T, Trendelenburg M. Cathepsin S inhibition suppresses autoimmune-triggered inflammatory responses in macrophages. Biochem Pharmacol. 2017;146:151–64.PubMedCrossRef
143.
Chen H, Wang J, Xiang MX, Lin Y, He A, Jin CN, Guan J, Sukhova GK, Libby P, Wang JA, Shi GP. Cathepsin S-mediated fibroblast trans-differentiation contributes to left ventricular remodelling after myocardial infarction. Cardiovasc Res. 2013;100:84–94.PubMedPubMedCentralCrossRef
144.
Liu CL, Guo J, Zhang X, Sukhova GK, Libby P, Shi GP. Cysteine protease cathepsins in cardiovascular disease: from basic research to clinical trials. Nat Rev Cardiol. 2018;15:351–70.PubMedCrossRef
145.
Lai CH, Chang JY, Wang KC, Lee FT, Wu HL, Cheng TL. Pharmacological inhibition of Cathepsin S suppresses abdominal aortic aneurysm in mice. Eur J Vasc Endovasc Surg. 2020.
146.
Rodgers KJ, Watkins DJ, Miller AL, Chan PY, Karanam S, Brissette WH, Long CJ, Jackson CL. Destabilizing role of cathepsin S in murine atherosclerotic plaques. Arterioscler Thromb Vasc Biol. 2006;26:851–6.PubMedCrossRef
147.
Sukhova GK, Zhang Y, Pan JH, Wada Y, Yamamoto T, Naito M, Kodama T, Tsimikas S, Witztum JL, Lu ML, et al. Deficiency of cathepsin S reduces atherosclerosis in LDL receptor-deficient mice. J Clin Invest. 2003;111:897–906.PubMedPubMedCentralCrossRef
148.
de Nooijer R, Bot I, von der Thusen JH, Leeuwenburgh MA, Overkleeft HS, Kraaijeveld AO, Dorland R, van Santbrink PJ, van Heiningen SH, Westra MM, et al. Leukocyte cathepsin S is a potent regulator of both cell and matrix turnover in advanced atherosclerosis. Arterioscler Thromb Vasc Biol. 2009;29:188–94.PubMedCrossRef
149.
Lohoefer F, Reeps C, Lipp C, Rudelius M, Zimmermann A, Ockert S, Eckstein HH, Pelisek J. Histopathological analysis of cellular localization of cathepsins in abdominal aortic aneurysm wall. Int J Exp Pathol. 2012;93:252–8.PubMedPubMedCentralCrossRef
150.
Wang H, Meng X, Piao L, Inoue A, Xu W, Yu C, Nakamura K, Hu L, Sasaki T, Wu H, et al. Cathepsin S deficiency mitigated chronic stress-related Neointimal hyperplasia in mice. J Am Heart Assoc. 2019;8:e011994.PubMedPubMedCentral
151.
Jobs E, Riserus U, Ingelsson E, Sundstrom J, Jobs M, Nerpin E, Iggman D, Basu S, Larsson A, Lind L, Arnlov J. Serum cathepsin S is associated with decreased insulin sensitivity and the development of type 2 diabetes in a community-based cohort of elderly men. Diabetes Care. 2013;36:163–5.PubMedCrossRef
152.
Xu L, Feng B, Wang H, Li X. Multiple statistical methods for assessing differential gene expression in microarray data of diabetic model rats to predict the molecular mechanism of atorvastatin on anti-atherogenesis. Exp Clin Endocrinol Diabetes. 2013;121:272–9.PubMedCrossRef
153.
Chen L, Lu B, Yang Y, Zhang W, Wang X, Zhou H, Wen J, Yang Z, Hu R. Elevated circulating cathepsin S levels are associated with metabolic syndrome in overweight and obese individuals. Diabetes Metab Res Rev. 2019;35:e3117.PubMed
154.
Larsson A, Svensson MB, Ronquist G, Akerfeldt T. Life style intervention in moderately overweight individuals is associated with decreased levels of cathepsins L and S in plasma. Ann Clin Lab Sci. 2014;44:283–5.PubMed
155.
Kumar Vr S, Darisipudi MN, Steiger S, Devarapu SK, Tato M, Kukarni OP, Mulay SR, Thomasova D, Popper B, Demleitner J, et al. Cathepsin S cleavage of protease-activated Receptor-2 on endothelial cells promotes microvascular diabetes complications. J Am Soc Nephrol. 2016;27:1635–49.PubMedCrossRef
156.
Lee AL, Rawlings S, Bennett KA, Armstrong D. Pain and its clinical associations in individuals with cystic fibrosis: a systematic review. Chron Respir Dis. 2016;13:102–17.PubMedPubMedCentralCrossRef
157.
van Dam van Isselt EF, Groenewegen-Sipkema KH, Spruit-van Eijk M, Chavannes NH, de Waal MW, Janssen DJ, Achterberg WP. Pain in patients with COPD: a systematic review and meta-analysis. BMJ Open. 2014;4:e005898.CrossRef
158.
Zhang J, Patel JM. Role of the CX3CL1-CX3CR1 axis in chronic inflammatory lung diseases. Int J Clin Exp Med. 2010;3:233–44.PubMedPubMedCentral
159.
Clark AK, Yip PK, Grist J, Gentry C, Staniland AA, Marchand F, Dehvari M, Wotherspoon G, Winter J, Ullah J, et al. Inhibition of spinal microglial cathepsin S for the reversal of neuropathic pain. Proc Natl Acad Sci U S A. 2007;104:10655–60.PubMedPubMedCentralCrossRef
160.
Cattaruzza F, Lyo V, Jones E, Pham D, Hawkins J, Kirkwood K, Valdez-Morales E, Ibeakanma C, Vanner SJ, Bogyo M, Bunnett NW. Cathepsin S is activated during colitis and causes visceral hyperalgesia by a PAR2-dependent mechanism in mice. Gastroenterology. 1864-1874;2011(141):e1861–3.
161.
Stoka V, Turk V, Turk B. Lysosomal cathepsins and their regulation in aging and neurodegeneration. Ageing Res Rev. 2016;32:22–37.PubMedCrossRef
162.
Schwarz G, Boehncke W-HH, Braun M, Schröter CJ, Burster T, Flad T, Dressel D, Weber E, Schmid H, Kalbacher H. Cathepsin S activity is detectable in human keratinocytes and is selectively upregulated upon stimulation with interferon-gamma. J Invest Dermatol. 2002;119:44–9.PubMedCrossRef
163.
Storm van’s Gravesande K, Layne MD, Ye Q, Le L, Baron RM, Perrella MA, Santambrogio L, Silverman ES, Riese RJ. IFN regulatory Factor-1 regulates IFN-γ-dependent Cathepsin S expression. J Immunol. 2002;168:4488–94.PubMedCrossRef
164.
Wang Y, Baron RM, Zhu G, Joo M, Christman JW, Silverman ES, Perrella MA, Riese RJ, Cernadas M. PU.1 regulates Cathepsin S expression in professional APCs. J Immunol. 2006;176:275–83.PubMedCrossRef
165.
Fiebiger E, Meraner P, Weber E, Fang IF, Stingl G, Ploegh H, Maurer D. Cytokines regulate proteolysis in major histocompatibility complex class II-dependent antigen presentation by dendritic cells. J Exp Med. 2001;193:881–92.PubMedPubMedCentralCrossRef
166.
Wallace AM, Hardigan A, Geraghty P, Salim S, Gaffney A, Thankachen J, Arellanos L, D'armiento JM, Foronjy RF. Protein phosphatase 2A regulates innate immune and proteolytic responses to cigarette smoke exposure in the lung. Toxicol Sci. 2012;126:589–99.PubMedPubMedCentralCrossRef
167.
Sontag E, Luangpirom A, Hladik C, Mudrak I, Ogris E, Speciale S, White CL. Altered expression levels of the protein phosphatase 2A ABαC enzyme are associated with Alzheimer disease pathology. J Neuropathol Exp Neurol. 2004;63:287–301.PubMedCrossRef
168.
Sangodkar J, Farrington CC, McClinch K, Galsky MD, Kastrinsky DB, Narla G. All roads lead to PP2A: exploiting the therapeutic potential of this phosphatase. FEBS J. 2016;283:1004–24.PubMedCrossRef
169.
Hayashi Y, Koyanagi S, Kusunose N, Okada R, Wu Z, Tozaki-Saitoh H, Ukai K, Kohsaka S, Inoue K, Ohdo S, Nakanishi H. The intrinsic microglial molecular clock controls synaptic strength via the circadian expression of cathepsin S. Sci Rep. Sci Rep. 2013;3:2744.
170.
Cimerman N, Brguljan PM, Krasovec M, Suskovic S, Kos J, Krašovec M, Šuškovič S, Kos J. Circadian and concentration profile of cathepsin S in sera from healthy subjects and asthmatic patients. Pflugers Arch. 2001;442:R204–6.PubMedCrossRef
171.
Stellos K, Gatsiou A, Stamatelopoulos K, Perisic Matic L, John D, Lunella FF, Jaé N, Rossbach O, Amrhein C, Sigala F, et al. Adenosine-to-inosine RNA editing controls cathepsin S expression in atherosclerosis by enabling HuR-mediated post-transcriptional regulation. Nat Med. 2016;22:1140–50.PubMedCrossRef
172.
Yang JH, Luo X, Nie Y, Su Y, Zhao Q, Kabir K, Zhang D, Rabinovici R. Widespread inosine-containing mRNA in lymphocytes regulated by ADAR1 in response to inflammation. Immunology. 2003;109:15–23.PubMedPubMedCentralCrossRef
173.
Nevo-Caspi Y, Amariglio N, Rechavi G, Paret G. A-to-I RNA editing is induced upon hypoxia. Shock. 2011;35:585–9.PubMedCrossRef
174.
Ross EA, Smallie T, Ding Q, O’Neil JD, Cunliffe HE, Tang T, Rosner DR, Klevernic I, Morrice NA, Monaco C, et al. Dominant suppression of inflammation via targeted mutation of the mRNA destabilizing protein Tristetraprolin. J Immunol. 2015;195:265–76.PubMedPubMedCentralCrossRef
175.
Bollmann F, Wu Z, Oelze M, Siuda D, Xia N, Henke J, Daiber A, Li H, Stumpo DJ, Blackshear PJ, et al. Endothelial dysfunction in tristetraprolin-deficient mice is not caused by enhanced tumor necrosis factor-α expression. J Biol Chem. 2014;289:15653–65.PubMedPubMedCentralCrossRef
176.
Rahman MM, Rumzhum NN, Hansbro PM, Morris JC, Clark AR, Verrills NM, Ammit AJ. Activating protein phosphatase 2A (PP2A) enhances tristetraprolin (TTP) anti-inflammatory function in A549 lung epithelial cells. Cellular Signal. 2016;28:325–34.CrossRef
177.
Nair PM, Starkey MR, Haw TJ, Liu G, Horvat JC, Morris JC, Verrills NM, Clark AR, Ammit AJ, Hansbro PM. Targeting PP2A and proteasome activity ameliorates features of allergic airway disease in mice. Allergy. 2017;72:1891–903.PubMedCrossRef
178.
Pires D, Bernard EM, Pombo JP, Carmo N, Fialho C, Gutierrez MG, Bettencourt P, Anes E. Mycobacterium tuberculosis modulates miR-106b-5p to control Cathepsin S expression resulting in higher pathogen survival and poor T-cell activation. Front Immunol. 2017;8:1819.
179.
Sendide K, Deghmane A-E, Pechkovsky D, Av-Gay Y, Talal A, Hmama Z. Mycobacterium bovis BCG attenuates surface expression of mature class II molecules through IL-10-dependent inhibition of Cathepsin S the. J Immunol. 2005;175:5324–32.PubMedCrossRef
180.
181.
Pai RK, Convery M, Hamilton TA, Boom WH, Harding CV. Inhibition of IFN-γ-induced class II Transactivator expression by a 19-kDa lipoprotein from Mycobacterium tuberculosis : a potential mechanism for immune evasion. J Immunol. 2003;171:175–84.PubMedCrossRef
182.
Reddy AT, Lakshmi SP, Muchumarri RR, Reddy RC. Nitrated fatty acids reverse cigarette smoke-induced alveolar macrophage activation and inhibit protease activity via electrophilic S-alkylation. PLoS One. 2016;11:e0153336.PubMedPubMedCentralCrossRef
183.
184.
Fonović M, Turk B. Cysteine cathepsins and extracellular matrix degradation. Biochim Biophys Acta. 2014;1840:2560–70.PubMedCrossRef
185.
Magister Š, Obermajer N, Mirković B, Švajger U, Renko M, Softić A, Romih R, Colbert JD, Watts C, Kos J. Regulation of cathepsins S and L by cystatin F during maturation of dendritic cells. Eur J Cell Biol. 2012;91:391–401.PubMedCrossRef
186.
187.
188.
Balce DR, Allan ERO, McKenna N, Yates RM. γ-Interferon-inducible lysosomal thiol reductase (GILT) maintains phagosomal proteolysis in alternatively activated macrophages. J Biol Chem. 2014;289:31891–904.PubMedPubMedCentralCrossRef
189.
Phipps-Yonas H, Semik V, Hastings KT. GILT expression in B cells diminishes cathepsin S steady-state protein expression and activity. Eur J Immunol. 2013;43:65–74.PubMedCrossRef
190.
Xu Y, Lindemann P, Vega-Ramos J, Zhang JG, Villadangos JA. Developmental regulation of synthesis and dimerization of the amyloidogenic protease inhibitor cystatin C in the hematopoietic system. J Biol Chem. 2014;289:9730–40.PubMedPubMedCentralCrossRef
191.
Tsai JY, Lee MJ, Dah-Tsyr Chang M, Huang H. The effect of catalase on migration and invasion of lung cancer cells by regulating the activities of cathepsin S, L, and K. Exp Cell Res. 2014;323:28–40.PubMedCrossRef
192.
Steimle A, Gronbach K, Beifuss B, Schäfer A, Harmening R, Bender A, Maerz JK, Lange A, Michaelis L, Maurer A, et al. Symbiotic gut commensal bacteria act as host cathepsin S activity regulators. J Autoimmun. 2016;75:82–95.PubMedCrossRef
193.
Lalmanach G, Saidi A, Bigot P, Chazeirat T, Lecaille F, Wartenberg M. Regulation of the proteolytic activity of cysteine Cathepsins by oxidants. Int J Mol Sci. 2020;21(6):1944.
194.
Guo CJ, Chang FY, Wyche TP, Backus KM, Acker TM, Funabashi M, Taketani M, Donia MS, Nayfach S, Pollard KS, et al. Discovery of reactive microbiota-derived metabolites that inhibit host proteases. Cell. 2017;168:517–526.e518.PubMedPubMedCentralCrossRef
195.
Ogrinc T, Dolenc I, Ritonja A, Turk V. Purification of the complex of cathepsin L and the MHC class II-associated invariant chain fragment from human kidney. FEBS Lett. 1993;336:555–9.PubMedCrossRef
196.
Mihelič M, Doberšek A, Gunčar G, Turk D. Inhibitory fragment from the p41 form of invariant chain can regulate activity of cysteine cathepsins in antigen presentation. J Biol Chem. 2008;283:14453–60.PubMedCrossRef
197.
Saegusa K, Ishimaru N, Yanagi K, Arakaki R, Ogawa K, Saito I, Katunuma N, Hayashi Y. Cathepsin S inhibitor prevents autoantigen presentation and autoimmunity. J Clin Invest. 2002;110:361–9.PubMedPubMedCentralCrossRef
198.
Xu J, Wang H, Ding K, Lu X, Li T, Wang J, Wang C, Wang J. Inhibition of cathepsin S produces neuroprotective effects after traumatic brain injury in mice. Mediat Inflamm. 2013;2013:187873.
199.
Palermo C, Joyce JA. Cysteine cathepsin proteases as pharmacological targets in cancer. Trends Pharmacol Sci. 2008;29:22–8.PubMedCrossRef
200.
Lee-Dutra A, Wiener DK, Sun S. Cathepsin S inhibitors: 2004 - 2010. Expert Opin Ther Pat. 2011;21:311–37.PubMedCrossRef
201.
Burden RE, Gormley JA, Kuehn D, Ward C, Kwok HF, Gazdoiu M, McClurg A, Jaquin TJ, Johnston JA, Scott CJ, Olwill SA. Inhibition of Cathepsin S by Fsn0503 enhances the efficacy of chemotherapy in colorectal carcinomas. Biochimie. 2012;94:487–93.PubMedCrossRef
202.
Ward C, Kuehn D, Burden RE, Gormley JA, Jaquin TJ, Gazdoiu M, Small D, Bicknell R, Johnston JA, Scott CJ, Olwill SA. Antibody targeting of Cathepsin S inhibits angiogenesis and synergistically enhances anti-VEGF. PLoS One. 2010;5:e12543.PubMedPubMedCentralCrossRef
203.
Burden RE, Snoddy P, Buick RJ, Johnston JA, Walker B, Scott CJ. Recombinant cathepsin S propeptide attenuates cell invasion by inhibition of cathepsin L-like proteases in tumor microenvironment. Mol Cancer Ther. 2008;7:538–47.PubMedCrossRef
204.
Kopitz C, Anton M, Gansbacher B, Krüger A. Reduction of experimental human fibrosarcoma lung metastasis in mice by adenovirus-mediated cystatin C overexpression in the host. Cancer Res. 2005;65:8608–12.PubMedCrossRef
205.
Sokol JP, Schiemann WP. Cystatin C antagonizes transforming growth factor β signaling in normal and cancer cells. Mol Cancer Res. 2004;2:183–95.PubMed
206.
Wang S, Xie Y, Yang X, Wang X, Yan K, Zhong Z, Wang X, Xu Y, Zhang Y, Liu F, Shen J. Therapeutic potential of recombinant cystatin from Schistosoma japonicum in TNBS-induced experimental colitis of mice. Parasit Vectors. 2016;9:6.PubMedPubMedCentralCrossRef
207.
208.
Skurkovich B, Skurkovich S. Inhibition of IFN-gamma as a method of treatment of various autoimmune diseases, including skin diseases. Ernst Schering Res Found Workshop. 2006;(56):1–27.
209.
McClinch K, Avelar RA, Callejas D, Izadmehr S, Wiredja D, Perl A, Sangodkar J, Kastrinsky DB, Schlatzer D, Cooper M, et al. Small-molecule activators of protein phosphatas 2A for the treatment of castration-resistant prostate cancer. Cancer Res. 2018;78:2065–80.PubMedPubMedCentralCrossRef
210.
Sangodkar J, Perl A, Tohme R, Kiselar J, Kastrinsky DB, Zaware N, Izadmehr S, Mazhar S, Wiredja DD, O'Connor CM, et al. Activation of tumor suppressor protein PP2A inhibits KRAS-driven tumor growth. J Clin Invest. 2017;127:2081–90.PubMedPubMedCentralCrossRef
211.
McNeely TB, Dealy M, Dripps DJ, Orenstein JM, Eisenberg SP, Wahl SM. Secretory leukocyte protease inhibitor: a human saliva protein exhibiting anti-human immunodeficiency virus 1 activity in vitro. J Clin Invest. 1995;96:456–64.PubMedPubMedCentralCrossRef
212.
Hosakote YM, Liu T, Castro SM, Garofalo RP, Casola A. Respiratory syncytial virus induces oxidative stress by modulating antioxidant enzymes. Am J Respir Cell Mol Biol. 2009;41:348–57.PubMedPubMedCentralCrossRef
213.
Chen J, Parsons S, Brautigan DL. Tyrosine phosphorylation of protein phosphatase 2A in response to growth stimulation and v-src transformation of fibroblasts. J Biol Chem. 1994;269:7957–62.PubMed
214.
Barik S, McLean T, Dupuy LC. Phosphorylation of Ser232 directly regulates the transcriptional activity of the P protein of human respiratory syncytial virus: phosphorylation of Ser237 may play an accessory role. Virology. 1995;213:405–12.PubMedCrossRef
215.
Vogl T, Tenbrock K, Ludwig S, Leukert N, Ehrhardt C, van Zoelen MA, Nacken W, Foell D, van der Poll T, Sorg C, Roth J. Mrp8 and Mrp14 are endogenous activators of toll-like receptor 4, promoting lethal, endotoxin-induced shock. Nat Med. 2007;13:1042–9.PubMedCrossRef
216.
Kelschenbach JL, Saini M, Hadas E, Gu CJ, Chao W, Bentsman G, Hong JP, Hanke T, Sharer LR, Potash MJ, Volsky DJ. Mice chronically infected with chimeric HIV resist peripheral and brain superinfection: a model of protective immunity to HIV. J NeuroImmune Pharmacol. 2012;7:380–7.PubMedCrossRef
217.
Hadas E, Borjabad A, Chao W, Saini M, Ichiyama K, Potash MJ, Volsky DJ. Testing antiretroviral drug efficacy in conventional mice infected with chimeric HIV-1. AIDS. 2007;21:905–9.PubMedCrossRef
218.
Schonbeck U, Mach F, Libby P. Generation of biologically active IL-1 beta by matrix metalloproteinases: a novel caspase-1-independent pathway of IL-1 beta processing. J Immunol. 1998;161:3340–6.PubMed
219.
Guma M, Ronacher L, Liu-Bryan R, Takai S, Karin M, Corr M. Caspase 1-independent activation of interleukin-1beta in neutrophil-predominant inflammation. Arthritis Rheum. 2009;60:3642–50.PubMedPubMedCentralCrossRef
220.
Ramaswamy M, Groskreutz DJ, Look DC. Recognizing the importance of respiratory syncytial virus in chronic obstructive pulmonary disease. COPD. 2009;6:64–75.PubMedCrossRef
221.
Tsai SY, Segovia JA, Chang TH, Morris IR, Berton MT, Tessier PA, Tardif MR, Cesaro A, Bose S. DAMP molecule S100A9 acts as a molecular pattern to enhance inflammation during influenza a virus infection: role of DDX21-TRIF-TLR4-MyD88 pathway. PLoS Pathog. 2014;10:e1003848.PubMedPubMedCentralCrossRef
222.
Lee JJ, Jacobsen EA, Ochkur SI, McGarry MP, Condjella RM, Doyle AD, Luo H, Zellner KR, Protheroe CA, Willetts L, et al. Human versus mouse eosinophils: "that which we call an eosinophil, by any other name would stain as red". J Allergy Clin Immunol. 2012;130:572–84.PubMedPubMedCentralCrossRef
223.
Gringhuis SI, van der Vlist M, van den Berg LM, den Dunnen J, Litjens M, Geijtenbeek TB. HIV-1 exploits innate signaling by TLR8 and DC-SIGN for productive infection of dendritic cells. Nat Immunol. 2010;11:419–26.PubMedCrossRef
224.
Theron M, Bentley D, Nagel S, Manchester M, Gerg M, Schindler T, Silva A, Ecabert B, Teixeira P, Perret C, Reis B. Pharmacodynamic monitoring of RO5459072, a small molecule inhibitor of cathepsin S. Front Immunol. 2017;8:806.
225.
Payne CD, Deeg MA, Chan M, Tan LH, LaBell ES, Shen T, DeBrota DJ. Pharmacokinetics and pharmacodynamics of the cathepsin S inhibitor, LY3000328, in healthy subjects. Br J Clin Pharmacol. 2014;78:1334–42.PubMedPubMedCentralCrossRef
226.
Kramer L, Turk D, Turk B. The future of cysteine Cathepsins in disease management. Trends Pharmacol Sci. 2017;38:873–98.PubMedCrossRef
227.
Wilder CL, Walton C, Watson V, Stewart FAA, Johnson J, Peyton SR, Payne CK, Odero-Marah V, Platt MO. Differential cathepsin responses to inhibitor-induced feedback: E-64 and cystatin C elevate active cathepsin S and suppress active cathepsin L in breast cancer cells. Int J Biochem Cell Biol. 2016;79:199–208.PubMedPubMedCentralCrossRef
228.
Foronjy RF, Taggart CC, Dabo AJ, Weldon S, Cummins N, Geraghty P. Type-I interferons induce lung protease responses following respiratory syncytial virus infection via RIG-I-like receptors. Mucosal Immunol. 2015;8:161–75.PubMedCrossRef
229.
Gall CL, Bonnelye E, Clézardin P. Cathepsin K inhibitors as treatment of bone metastasis. Curr Opin Support Palliat Care. 2008;2:218–22.PubMedCrossRef
230.
Brömme D, Lecaille F. Cathepsin K inhibitors for osteoporosis and potential off-target effects. Exp Opin Invest Drugs. 2009;18:585–600.CrossRef
Metadata
Title
Cathepsin S: investigating an old player in lung disease pathogenesis, comorbidities, and potential therapeutics
Authors
Ryan Brown
Sridesh Nath
Alnardo Lora
Ghassan Samaha
Ziyad Elgamal
Ryan Kaiser
Clifford Taggart
Sinéad Weldon
Patrick Geraghty
Publication date
01-12-2020
Publisher
BioMed Central
Published in
Respiratory Research / Issue 1/2020
Electronic ISSN: 1465-993X
DOI
https://doi.org/10.1186/s12931-020-01381-5

Other articles of this Issue 1/2020

Respiratory Research 1/2020 Go to the issue

Research

Single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol and umeclidinium/vilanterol in patients with COPD: results on cardiovascular safety from the IMPACT trial

Research

Quantitative CT-based image registration metrics provide different ventilation and lung motion patterns in prone and supine positions in healthy subjects

Research

Persisting alterations of iron homeostasis in COVID-19 are associated with non-resolving lung pathologies and poor patients’ performance: a prospective observational cohort study

Research

Value of metalloproteinases in predicting COPD in heavy urban smokers

Research

Prognostic value of NT-proBNP in patients with severe COVID-19

Research

Nasal microbiota dominated by Moraxella spp. is associated with respiratory health in the elderly population: a case control study
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits